A Type 2 Diabetes-Associated Functional Regulatory Variant in a Pancreatic Islet Enhancer at the <i>ADCY5</i> Locus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28684635.
- Also identified by DOI 10.2337/db17-0464 and PMC identifier 5860374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Molecular mechanisms remain unknown for most type 2 diabetes genome-wide association study identified loci. Variants associated with type 2 diabetes and fasting glucose levels reside in introns of <i>ADCY5</i>, a gene that encodes adenylate cyclase 5. Adenylate cyclase 5 catalyzes the production of cyclic AMP, which is a second messenger molecule involved in cell signaling and pancreatic β-cell insulin secretion. We demonstrated that type 2 diabetes risk alleles are associated with decreased <i>ADCY5</i> expression in human islets and examined candidate variants for regulatory function. rs11708067 overlaps a predicted enhancer region in pancreatic islets. The type 2 diabetes risk rs11708067-A allele showed fewer H3K27ac ChIP-seq reads in human islets, lower transcriptional activity in reporter assays in rodent β-cells (rat 832/13 and mouse MIN6), and increased nuclear protein binding compared with the rs11708067-G allele. Homozygous deletion of the orthologous enhancer region in 832/13 cells resulted in a 64% reduction in expression level of <i>Adcy5</i>, but not adjacent gene <i>Sec22a</i>, and a 39% reduction in insulin secretion. Together, these data suggest that rs11708067-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced <i>ADCY5</i> expression and impaired insulin secretion.
Medical subject headings
- Adenylyl Cyclases
- Diabetes Mellitus, Type 2
- Gene Expression Regulation
- Genetic Variation
- Genome-Wide Association Study
- Islets of Langerhans